Each Tablet Contains Deucravacitinib INN 6mg.
It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The absolute oral bioavailability of Deucravacitinib was 98% and ranged from 2 to 3 hours in healthy patients. The volume of Sarbdice at steady state is 140 L. The terminal half-life is 10 hours. The renal clearece ranged from 27 to 54 mL/Minute. Deucravacitinib is meabolbed by plochrome P-450 (CYP) 1A2. Approximately 13% and 26% of De Deucasacitinib dose excreted by urine and feces.
Each Tablet Contains Deucravacitinib INN 6mg.
It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The absolute oral bioavailability of Deucravacitinib was 98% and ranged from 2 to 3 hours in healthy patients. The volume of Sarbdice at steady state is 140 L. The terminal half-life is 10 hours. The renal clearece ranged from 27 to 54 mL/Minute. Deucravacitinib is meabolbed by plochrome P-450 (CYP) 1A2. Approximately 13% and 26% of De Deucasacitinib dose excreted by urine and feces.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.